Opinion of the Transparency Council – combining drug programmes B.29 and B.46
At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 110/2022 on the legitimacy of combining multiple sclerosis treatment drug programmes, i.e. B.29 and B.46.
Publication with the minutes of the Transparency Council meeting